ZNTL
Zentalis Pharmaceuticals, Inc.
Price Chart
Latest Quote
$2.51
Current Price| Previous Close | $2.43 |
| Open | $2.40 |
| Day High | $2.64 |
| Day Low | $2.35 |
| Volume | 818,617 |
Stock Information
| Shares Outstanding | 64.75M |
| Total Debt | $40.46M |
| Cash Equivalents | $280.70M |
| Revenue | $26.86M |
| Net Income | $-149.32M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $162.52M |
| EPS (TTM) | $-2.08 |
| Exchange | NGM |
đ Custom Metrics & Score
Score: 14/42| Debt to Equity | 0.12 |
| Debt to Earnings | -0.24 |
| Current Ratio | 7.32 |
| Quick Ratio | 7.13 |
| Profit Margin | -245.96% |
| Return on Equity | -49.18% |
| Avg FCF Growth | 1.70% |
| FCF Yield | -105.26% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $2.51 | 818,617 |
| 2026-01-30 | $2.43 | 465,000 |
| 2026-01-29 | $2.51 | 532,700 |
| 2026-01-28 | $2.56 | 535,700 |
| 2026-01-27 | $2.93 | 420,300 |
| 2026-01-26 | $2.80 | 843,300 |
| 2026-01-23 | $2.94 | 916,100 |
| 2026-01-22 | $3.25 | 1,052,600 |
| 2026-01-21 | $2.95 | 814,700 |
| 2026-01-20 | $2.87 | 786,300 |
| 2026-01-16 | $2.96 | 1,200,700 |
| 2026-01-15 | $3.16 | 1,394,100 |
| 2026-01-14 | $3.51 | 1,099,000 |
| 2026-01-13 | $3.48 | 1,651,900 |
| 2026-01-12 | $3.49 | 6,467,700 |
| 2026-01-09 | $3.74 | 12,396,900 |
| 2026-01-08 | $2.84 | 7,114,800 |
| 2026-01-07 | $2.42 | 4,673,700 |
| 2026-01-06 | $1.78 | 9,152,200 |
| 2026-01-05 | $1.37 | 369,000 |
About Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
đ° Latest News
Mitsui Sumitomo Continues to Build WR Berkley Stake
24/7 Wall St. âĸ 2026-01-13T13:45:57Z
A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Progress And Insider Buying
Simply Wall St. âĸ 2026-01-11T22:08:33Z
Following a 13% decline over last year, recent gains may please Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) institutional owners
Simply Wall St. âĸ 2026-01-08T12:27:58Z
We're Keeping An Eye On Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Rate
Simply Wall St. âĸ 2025-12-03T13:01:20Z
Pleasing Signs As A Number Of Insiders Buy Zentalis Pharmaceuticals Stock
Simply Wall St. âĸ 2025-10-06T15:39:01Z
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) is favoured by institutional owners who hold 59% of the company
Simply Wall St. âĸ 2025-07-23T16:34:04Z
Here's Why We're Watching Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation
Simply Wall St. âĸ 2025-06-26T12:04:54Z
Zentalis Pharmaceuticals First Quarter 2025 Earnings: US$0.67 loss per share (vs US$0.14 profit in 1Q 2024)
Simply Wall St. âĸ 2025-05-16T10:08:12Z
Zentalis Pharmaceuticals (ZNTL): Among Cheapest Stocks Insiders Are Buying Recently
Insider Monkey âĸ 2025-02-21T05:21:38Z
Zentalis Pharmaceuticals (ZNTL) Loses -46.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks âĸ 2025-02-03T14:35:08Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | $67,425,000 | $0 | $0 | $0 |
| Operating Revenue | $67,425,000 | $0 | $0 | $0 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Expenses | $254,883,000 | $253,941,000 | $227,287,000 | $216,542,000 |
| Other Income Expense | $21,768,000 | $-22,951,000 | $5,987,000 | $51,983,000 |
| Operating Expense | $254,883,000 | $253,941,000 | $227,287,000 | $216,542,000 |
| General And Administrative Expense | $87,115,000 | $64,351,000 | $54,553,000 | $40,941,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-165,839,000 | $-292,191,000 | $-236,806,000 | $-158,725,000 |
| Normalized Income | $-183,035,720 | $-269,285,902 | $-242,781,026 | $-210,604,034 |
| Net Income From Continuing And Discontinued Operation | $-165,839,000 | $-292,191,000 | $-236,806,000 | $-158,725,000 |
| Total Operating Income As Reported | $-191,194,000 | $-299,509,000 | $-227,287,000 | $-216,542,000 |
| Net Income Common Stockholders | $-165,839,000 | $-292,191,000 | $-236,806,000 | $-158,725,000 |
| Net Income | $-165,839,000 | $-292,191,000 | $-236,806,000 | $-158,725,000 |
| Net Income Including Noncontrolling Interests | $-165,867,000 | $-292,305,000 | $-237,113,000 | $-166,093,000 |
| Net Income Continuous Operations | $-165,867,000 | $-292,305,000 | $-237,113,000 | $-166,093,000 |
| Earnings From Equity Interest Net Of Tax | $0 | $-16,014,000 | $-16,282,000 | $-1,831,000 |
| Pretax Income | $-165,690,000 | $-276,892,000 | $-221,300,000 | $-164,559,000 |
| Special Income Charges | $-3,736,000 | $-45,568,000 | $0 | $51,582,000 |
| Operating Income | $-187,458,000 | $-253,941,000 | $-227,287,000 | $-216,542,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-2.33 | $-4.47 | $-4.48 | $-3.72 |
| Basic EPS | $-2.33 | $-4.47 | $-4.48 | $-3.72 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $4,571,280 | $-45,902 | $11,974 | $103,966 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-207,937,000 | $-229,601,000 | $-231,848,000 | $-267,981,000 |
| Total Unusual Items | $21,768,000 | $-22,951,000 | $5,987,000 | $51,983,000 |
| Total Unusual Items Excluding Goodwill | $21,768,000 | $-22,951,000 | $5,987,000 | $51,983,000 |
| Reconciled Depreciation | $1,289,000 | $1,389,000 | $1,426,000 | $544,000 |
| EBITDA (Bullshit earnings) | $-186,169,000 | $-252,552,000 | $-225,861,000 | $-215,998,000 |
| EBIT | $-187,458,000 | $-253,941,000 | $-227,287,000 | $-216,542,000 |
| Diluted Average Shares | $71,080,000 | $65,409,000 | $52,857,000 | $42,688,000 |
| Basic Average Shares | $71,080,000 | $65,409,000 | $52,857,000 | $42,688,000 |
| Diluted NI Availto Com Stockholders | $-165,839,000 | $-292,191,000 | $-236,806,000 | $-158,725,000 |
| Minority Interests | $28,000 | $114,000 | $307,000 | $7,368,000 |
| Tax Provision | $177,000 | $-601,000 | $-469,000 | $-297,000 |
| Impairment Of Capital Assets | $3,736,000 | $0 | $0 | - |
| Gain On Sale Of Security | $25,504,000 | $22,617,000 | $5,987,000 | $401,000 |
| Research And Development | $167,768,000 | $189,590,000 | $172,734,000 | $175,601,000 |
| Selling General And Administration | $87,115,000 | $64,351,000 | $54,553,000 | $40,941,000 |
| Other Gand A | $87,115,000 | $64,351,000 | $54,553,000 | $40,941,000 |
| Gain On Sale Of Business | - | $0 | $0 | $51,582,000 |
| Other Special Charges | - | $45,568,000 | - | - |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $337,186,000 | $433,548,000 | $430,067,000 | $360,218,000 |
| Total Assets | $430,337,000 | $551,688,000 | $539,310,000 | $454,507,000 |
| Total Non Current Assets | $44,271,000 | $54,970,000 | $87,377,000 | $103,737,000 |
| Other Non Current Assets | $7,044,000 | $9,499,000 | $12,350,000 | $9,667,000 |
| Goodwill And Other Intangible Assets | $0 | $3,736,000 | $3,736,000 | $3,736,000 |
| Current Assets | $386,066,000 | $496,718,000 | $451,933,000 | $350,770,000 |
| Other Current Assets | $9,982,000 | $13,799,000 | $14,562,000 | $10,640,000 |
| Receivables | $5,000,000 | $0 | $7,041,000 | $4,439,000 |
| Other Receivables | $5,000,000 | - | $6,533,000 | $4,181,000 |
| Cash Cash Equivalents And Short Term Investments | $371,084,000 | $482,919,000 | $437,371,000 | $339,887,000 |
| Cash And Cash Equivalents | $33,901,000 | $28,038,000 | $43,069,000 | $59,714,000 |
| Non Current Prepaid Assets | - | - | $9,723,000 | $7,040,000 |
| Restricted Cash | - | - | $0 | $243,000 |
| Prepaid Assets | - | - | $14,562,000 | $10,640,000 |
| Accrued Interest Receivable | - | - | $508,000 | $258,000 |
| Accounts Receivable | - | - | - | $4,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $39,577,000 | $43,150,000 | $45,166,000 | $44,459,000 |
| Long Term Debt And Capital Lease Obligation | $39,577,000 | $43,150,000 | $45,166,000 | $44,459,000 |
| Current Debt And Capital Lease Obligation | - | - | - | $1,453,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $93,151,000 | $114,297,000 | $105,286,000 | $90,025,000 |
| Total Non Current Liabilities Net Minority Interest | $40,426,000 | $44,930,000 | $48,639,000 | $46,081,000 |
| Other Non Current Liabilities | $849,000 | $1,780,000 | $2,620,000 | - |
| Current Liabilities | $52,725,000 | $69,367,000 | $56,647,000 | $43,944,000 |
| Payables And Accrued Expenses | $52,725,000 | $69,367,000 | $56,647,000 | $43,944,000 |
| Payables | $7,438,000 | $14,926,000 | $11,247,000 | $11,590,000 |
| Accounts Payable | $7,438,000 | $14,926,000 | $11,247,000 | $11,590,000 |
| Non Current Deferred Liabilities | - | $0 | $853,000 | $1,622,000 |
| Non Current Deferred Taxes Liabilities | - | $0 | $853,000 | $1,622,000 |
| Total Tax Payable | - | - | - | $971,000 |
| Income Tax Payable | - | - | - | $971,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $337,186,000 | $437,284,000 | $433,803,000 | $363,954,000 |
| Total Equity Gross Minority Interest | $337,186,000 | $437,391,000 | $434,024,000 | $364,482,000 |
| Stockholders Equity | $337,186,000 | $437,284,000 | $433,803,000 | $363,954,000 |
| Gains Losses Not Affecting Retained Earnings | $558,000 | $2,194,000 | $-1,353,000 | $-125,000 |
| Other Equity Adjustments | $558,000 | $2,194,000 | $-1,353,000 | $-125,000 |
| Retained Earnings | $-1,054,395,000 | $-888,556,000 | $-596,365,000 | $-359,559,000 |
| Long Term Equity Investment | - | $0 | $21,213,000 | $37,495,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $71,282,400 | $70,765,554 | $59,280,247 | $45,490,764 |
| Share Issued | $71,282,400 | $70,765,554 | $59,280,247 | $45,490,764 |
| Tangible Book Value | $337,186,000 | $433,548,000 | $430,067,000 | $360,218,000 |
| Invested Capital | $337,186,000 | $437,284,000 | $433,803,000 | $363,954,000 |
| Working Capital | $333,341,000 | $427,351,000 | $395,286,000 | $306,826,000 |
| Capital Lease Obligations | $39,577,000 | $43,150,000 | $45,166,000 | $44,459,000 |
| Total Capitalization | $337,186,000 | $437,284,000 | $433,803,000 | $363,954,000 |
| Minority Interest | $0 | $107,000 | $221,000 | $528,000 |
| Additional Paid In Capital | $1,390,952,000 | $1,323,576,000 | $1,031,462,000 | $723,593,000 |
| Capital Stock | $71,000 | $70,000 | $59,000 | $45,000 |
| Common Stock | $71,000 | $70,000 | $59,000 | $45,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $39,577,000 | $43,150,000 | $45,166,000 | $44,459,000 |
| Current Accrued Expenses | $45,287,000 | $54,441,000 | $45,400,000 | $32,354,000 |
| Goodwill | $0 | $3,736,000 | $3,736,000 | $3,736,000 |
| Net PPE | $37,227,000 | $41,735,000 | $50,078,000 | $52,839,000 |
| Accumulated Depreciation | $-4,274,000 | $-3,148,000 | $-2,060,000 | $-792,000 |
| Gross PPE | $41,501,000 | $44,883,000 | $52,138,000 | $53,631,000 |
| Leases | $4,168,000 | $4,235,000 | $4,891,000 | $4,515,000 |
| Construction In Progress | $0 | $173,000 | $37,000 | $34,000 |
| Other Properties | $35,910,000 | $38,985,000 | $44,995,000 | $46,748,000 |
| Machinery Furniture Equipment | $1,423,000 | $1,490,000 | $2,215,000 | $2,334,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $337,183,000 | $454,881,000 | $394,302,000 | $280,173,000 |
| Investments And Advances | - | $0 | $21,213,000 | $37,495,000 |
| Investmentsin Associatesat Cost | - | $0 | $21,213,000 | $37,495,000 |
| Investmentsin Joint Venturesat Cost | - | - | $21,213,000 | $37,495,000 |
| Current Capital Lease Obligation | - | - | - | $1,453,000 |
| Pensionand Other Post Retirement Benefit Plans Current | - | - | - | $9,250,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-171,081,000 | $-208,405,000 | $-166,299,000 | $-160,200,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-170,860,000 | $-207,822,000 | $-163,751,000 | $-154,093,000 |
| Cash Flow From Continuing Operating Activities | $-170,860,000 | $-207,822,000 | $-163,751,000 | $-154,093,000 |
| Operating Gains Losses | $-92,000 | $16,420,000 | $16,338,000 | $-48,084,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-221,000 | $-583,000 | $-2,548,000 | $-6,107,000 |
| Investing Cash Flow | $176,561,000 | $-44,458,000 | $-114,180,000 | $-18,115,000 |
| Cash Flow From Continuing Investing Activities | $176,561,000 | $-44,458,000 | $-114,180,000 | $-18,115,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Issuance Of Capital Stock | $349,000 | $237,303,000 | $261,043,000 | $179,667,000 |
| Financing Cash Flow | $108,000 | $237,303,000 | $261,043,000 | $178,521,000 |
| Cash Flow From Continuing Financing Activities | $108,000 | $237,303,000 | $261,043,000 | $178,521,000 |
| Net Other Financing Charges | $-241,000 | - | - | $-1,146,000 |
| Net Common Stock Issuance | $349,000 | $237,303,000 | $261,043,000 | $179,667,000 |
| Common Stock Issuance | $349,000 | $237,303,000 | $261,043,000 | $179,667,000 |
| Net Preferred Stock Issuance | - | - | $0 | $0 |
| Preferred Stock Issuance | - | - | $0 | $0 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Income Tax Paid Supplemental Data | $359,000 | $140,000 | $12,000 | $20,000 |
| End Cash Position | $36,528,000 | $30,719,000 | $45,696,000 | $62,584,000 |
| Beginning Cash Position | $30,719,000 | $45,696,000 | $62,584,000 | $56,271,000 |
| Changes In Cash | $5,809,000 | $-14,977,000 | $-16,888,000 | $6,313,000 |
| Net Investment Purchase And Sale | $176,717,000 | $-43,875,000 | $-111,632,000 | $2,312,000 |
| Sale Of Investment | $304,679,000 | $505,307,000 | $421,529,000 | $365,820,000 |
| Purchase Of Investment | $-127,962,000 | $-549,182,000 | $-533,161,000 | $-363,508,000 |
| Net PPE Purchase And Sale | $-156,000 | $-583,000 | $-2,548,000 | $-6,107,000 |
| Sale Of PPE | $65,000 | $0 | $0 | - |
| Purchase Of PPE | $-221,000 | $-583,000 | $-2,548,000 | $-6,107,000 |
| Change In Working Capital | $-16,540,000 | $5,864,000 | $13,252,000 | $16,605,000 |
| Change In Other Working Capital | $264,000 | $623,000 | $4,330,000 | $1,347,000 |
| Change In Payables And Accrued Expense | $-18,022,000 | $10,919,000 | $15,527,000 | $13,964,000 |
| Change In Payable | $-18,022,000 | $10,919,000 | $15,527,000 | $13,964,000 |
| Change In Account Payable | $-18,022,000 | $10,919,000 | $15,527,000 | $13,964,000 |
| Change In Prepaid Assets | $6,218,000 | $-5,678,000 | $-6,605,000 | $1,294,000 |
| Change In Receivables | $-5,000,000 | $0 | $0 | $413,000 |
| Changes In Account Receivables | $-5,000,000 | $0 | $0 | $413,000 |
| Other Non Cash Items | $-47,425,000 | $15,045,000 | - | - |
| Stock Based Compensation | $67,269,000 | $54,822,000 | $46,840,000 | $35,737,000 |
| Unrealized Gain Loss On Investment Securities | $-5,228,000 | $0 | $0 | - |
| Asset Impairment Charge | $3,736,000 | $4,953,000 | $0 | $8,800,000 |
| Amortization Of Securities | $-8,002,000 | $-13,157,000 | $-3,725,000 | $908,000 |
| Deferred Tax | $0 | $-853,000 | $-769,000 | $-2,510,000 |
| Deferred Income Tax | $0 | $-853,000 | $-769,000 | $-2,510,000 |
| Depreciation Amortization Depletion | $1,289,000 | $1,389,000 | $1,426,000 | $544,000 |
| Depreciation And Amortization | $1,289,000 | $1,389,000 | $1,426,000 | $544,000 |
| Earnings Losses From Equity Investments | $0 | $16,014,000 | $16,282,000 | $1,831,000 |
| Gain Loss On Sale Of PPE | $-13,000 | $406,000 | $56,000 | $15,000 |
| Gain Loss On Sale Of Business | $-79,000 | $0 | $0 | $-49,930,000 |
| Net Income From Continuing Operations | $-165,867,000 | $-292,305,000 | $-237,113,000 | $-166,093,000 |
| Net Business Purchase And Sale | - | $0 | $0 | $-14,320,000 |
| Purchase Of Business | - | $0 | $0 | $-14,320,000 |